Skip to main content
SpringerLink
Log in

Thyrotoxic graves’ disease with normal thyroidal technetium-99m pertechnetate uptake

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

We saw 24 thyrotoxic Graves’ patients with normal thyroidal uptake of technetium-99m pertechnetate (99mTc) out of 201 untreated thyrotoxic Graves’ patients seen over 4 years. The clinical and laboratory findings for these patients were studied and analysed.

Thyroid uptake and scintigraphic examinations by means of99mTc, TBII and TSab activity measurement clearly distinguished these patients from other thyrotoxic disorders (destruction-induced thyrotoxicosis and autonomously functioning thyroid lesions). Different from other disorders, these patients had not lower but normal thyroid uptake and also showed diffuse and discrete trapping into the enlarged glands.

These patients had significantly smaller goiters, a lower serum thyroid hormone level, and lower TBII and TSab activity, when compared with other high99mTc uptake groups with Graves’ disease, and their condition could be easily controlled with small amounts of antithyroid drugs.

Our study indicates that thyrotoxic Graves’ disease with normal99mTc uptake exists and99mTc uptake study and TBII activity measurement is very useful for the diagnosis. The normal99mTc uptake thyrotoxic Graves’ patient might be early stage patients with general Graves’ disease and their early discrimination from general Graves’ patients is very advantageous for treatment and prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hamburger JI: Solitary autonomously functioning thyroid lesions. Diagnosis, clinical features and pathogenic considerations.Am J Med 58: 740–748, 1975

    Article  PubMed  CAS  Google Scholar 

  2. Ishihara T, Mori T, Waseda N, et al: Histological, clinical and laboratory findings of acute exacerbation of granulomatous thyroiditis.Endocrinol Japon 34: 831–841, 1987

    CAS  Google Scholar 

  3. Ikekubo K, Hino M, Ito H, et al: Thyroid carcinoma in hot thyroid lesions onTc-99m sodium pertechnetate scans.Annals of nuclear medicine 3: 31–36, 1989

    Article  PubMed  CAS  Google Scholar 

  4. Fujita T, Kosaka T, Konishi J, et al: Development of routine procedure using pertechnetate for thyroid function test and its clinical evaluation.Jpn J Nucl Med 14: 827–840, 1977

    CAS  Google Scholar 

  5. Allen HC, Goodwin WE. The scintilation counter as an instrument forin vivo determination of thyroid weight.Radiology 58: 68–79, 1952

    PubMed  CAS  Google Scholar 

  6. Mori T, Ishihara T, Bito S, et al: Clinical evaluation of routinely applied highly sensitive TSH RIA.Folia Endocrinol Jpn 59: 941–948, 1983

    CAS  Google Scholar 

  7. Kasagi K, Konishi J, Iida Y, et al: A sensitive and practical assay for thyroid-stimulating antibodies using FRTL-5 thyroid cells.Acta Endocrinol (Copenh) 115: 30–36, 1987

    CAS  Google Scholar 

  8. Torizuka K, Mori T, Hamada S, et al: Thyroid function tests—Clinical aspects.Jpn J Clin Med 25: 1182–1190, 1967

    CAS  Google Scholar 

  9. Werner SC: Euthyroid Graves’ disease with early eye signs of Graves’ disease; their responses to L-triiodothyronine and thyrotropin.Amer J Med 18: 608–612, 1955

    Article  PubMed  CAS  Google Scholar 

  10. Liddle GW, Heyssel RM, Mckenzie JM. Graves’ disease without hyperthyroidism.Amer J Med 39: 845–848, 1965

    Article  PubMed  CAS  Google Scholar 

  11. Wyse EP, McConahey WM, Woolner LB, et al: Kearns Ophthalmology without hyperthyroidism in patients with histologic Hashimoto’s thyroiditis.J Clin Endocri 28: 1623–1629, 1968

    Article  CAS  Google Scholar 

  12. Gharib H, Mayberry WE: Diagnosis of Graves’ ophthalmopathy without hyperthyroidism: Long-acting thyroid stimulator (LATS) determination as Laboratory adjunct.Mayo Clin Proc 45: 444–449, 1970

    PubMed  CAS  Google Scholar 

  13. Tamai H, Nakagawa T, Ohsako N, et al: Changes in thyroid functions in patients with euthyroid Graves’ disease.J Clin Endocrinol Metab 50: 108–112, 1980

    Article  PubMed  CAS  Google Scholar 

  14. Kasagi K, Konishi J, Arai K, et al: A sensitive and practical assay for thyroid-stimulating antibodies using crude immunoglobulin fractions precipitated with polyethylene glycol.J Clin Endocrinol Metab 62: 855–862, 1986

    Article  PubMed  CAS  Google Scholar 

  15. Mori T, Imura H, Bito S, et al: Clinical usefulness of a highly sensitive enzyme-immunoassay of TSH.Clinical Endocrinology 27: 1–10, 1987

    Article  PubMed  CAS  Google Scholar 

  16. Kasagi K, Hatabu H, Tokuda Y, et al: Comparison of thyroid stimulating activities measured by cyclic AMP production, those by radioiodine uptake in FRTL-5 cells and TSH-binding inhibitory activities in patients with hyperthyroid and euthyroid Graves’ diseases.Acta Endocrinologica 117: 365–372, 1988

    PubMed  CAS  Google Scholar 

  17. Mori T, Kosugi S, Nishimura T, et al: Clinical and laboratory findings of Graves’ disease without persistent hyperthyroidism.Program of the 8th international congress of endocrinology. Kyoto, Japan, p 320, 1988

  18. Kasagi K, Konishi J, Iida Y, et al: A new in vitro assay for human thyroid stimulator using cultured thyroid cells: Effect of sodium chloride on adenosine 3′,5′-monophosphate increase. J Clin Endocrinol Metab 54: 108–114, 1982

    Article  PubMed  CAS  Google Scholar 

  19. Amino N, Yabu Y, Miki T, et al: Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves’ disease and destruction-induced thyrotoxicosis.J Clin Endocrinol Metab 53: 113–116, 1981

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Kobe City General Hospital, 4-6, Minatojima, Nakamachi, Chuo-ku, Kobe City, Japan

    Katsuji Ikekubo, Megumu Hino, Hidetomi Ito, Toshikiyo Koh, Takashi Ishihara & Hiroyuki Kurahachi

  2. Department of Nuclear Medicine and Medicine, Kyoto University School of Medicine, Kyoto, Japan

    Kanji Kasagi, Akinari Hidaka & Toru Mori

Authors
  1. Katsuji Ikekubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Megumu Hino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hidetomi Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshikiyo Koh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takashi Ishihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroyuki Kurahachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kanji Kasagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Akinari Hidaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Toru Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ikekubo, K., Hino, M., Ito, H. et al. Thyrotoxic graves’ disease with normal thyroidal technetium-99m pertechnetate uptake. Ann Nucl Med 4, 43–48 (1990). https://doi.org/10.1007/BF03164594

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03164594

Key words

Search

Navigation